---
title: "How Chronic Stress Shrinks Astrocyte Cilia — and What UCLA's Mouse Study Found"
slug: ucla-astrocyte-primary-cilia-chronic-stress-ponesimod-2026
category: health
category_label: "Health"
author: "BrainWavePost Staff"
date: 2026-09-11
tags: ["chronic stress", "astrocytes", "primary cilia", "amygdala", "ponesimod", "UCLA", "anxiety", "depression", "neuroscience"]
read_time_minutes: 9
canonical_url: https://brainwavepost.com/article/ucla-astrocyte-primary-cilia-chronic-stress-ponesimod-2026
source: BrainWavePost
---

# How Chronic Stress Shrinks Astrocyte Cilia — and What UCLA's Mouse Study Found

*Health · 2026-09-11 · BrainWavePost Staff · 9 min read*

> UCLA researchers found that chronic stress shortened sensory cilia on astrocytes in the mouse amygdala. Restoring the structures, including with the multiple-sclerosis drug ponesimod, improved some stress-related behaviors — but the work remains preclinical.

> **Preclinical research, not medical advice** _(note)_
>
> This study was conducted mainly in mice. Ponesimod is FDA-approved for relapsing forms of multiple sclerosis, not for anxiety, depression or chronic stress. The findings do not show that people should take it for a mental-health condition. [1][2]

## A different view of the stressed brain

Stress research has often centered on neurons, the electrically active cells that transmit signals. A UCLA-led study instead examined astrocytes — branching glial cells that support and influence neural circuits — in the amygdala, a region involved in fear, emotion and stress responses. [1]

The researchers focused on each astrocyte's primary cilium: a small, antenna-like projection that helps a cell detect and respond to signals in its environment. Separate government-indexed research has found that most astrocytes across the mouse brain carry a single primary cilium on the cell body and that ciliary signaling contributes to region-specific astrocyte development and function. [3]

In mouse models of chronic stress, UCLA's team found altered gene and protein activity in amygdala astrocytes, including changes tied to cilium function. The astrocytes' primary cilia were also physically shorter. [1] That makes the cilium more than a passive marker: it became a candidate mechanism through which stress might change how astrocytes communicate with the surrounding circuit.

- **14 days** — Duration of the principal chronic-stress paradigms reported by the UCLA team [1]
- **2 routes** — Chemogenetic and S1PR1-targeting approaches used to restore cilia-related function [1]
- **2021** — Year the FDA first approved ponesimod for relapsing forms of multiple sclerosis [2]

## What the experiments tested

The experiments used established mouse stress paradigms rather than people with anxiety or depression. UCLA reports that the researchers observed shorter primary cilia and molecular disruption in amygdala astrocytes after chronic stress, then tested whether manipulating signaling in those cells could restore cilium length and alter behavior. [1]

One route was chemogenetic: a laboratory method that lets researchers switch selected receptors on particular cells on or off. The other targeted a native G-protein-coupled receptor called sphingosine-1-phosphate receptor 1, or S1PR1. Both approaches restored astrocyte primary-cilium length, corrected many of the measured molecular alterations and improved some stress-related behaviors in the mice. [1]

The behavioral tests were proxies used in animal research, including measures interpreted as anxiety-like behavior, reduced preference for a normally rewarding stimulus and passive coping. They are not mouse versions of a clinical diagnosis. The National Institute of Mental Health cautions that animal models are most useful for testing defined biological hypotheses; no animal fully reproduces a human mental illness. [4][5]

## Why ponesimod entered the study

S1PR1 offered a practical pharmacological path because an existing medicine already acts on that receptor. Ponesimod, sold as Ponvory, is an oral sphingosine-1-phosphate receptor modulator. FDA prescribing information says it is indicated for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults. [2]

When UCLA researchers administered ponesimod to chronically stressed mice, they reported cilia restoration, molecular improvements and improvement in some stress-related behaviors similar to the other S1PR1-directed experiments. [1] This is a drug-repurposing clue, not a treatment result in patients.

That distinction matters because FDA approval applies to a particular drug, indication, population and evidence package. The agency's label also lists contraindications, warnings and required dose titration. An approved multiple-sclerosis medicine is not automatically established as safe or effective for a psychiatric use. [2]

## What the human tissue analysis adds

The team also examined gene activity in human amygdala tissue. UCLA reports that cilium-related genes were expressed in human amygdala astrocytes and that expression of many such genes was disrupted in tissue from people diagnosed with major depressive disorder, bipolar disorder and psychosis-related disorders. S1PR1 was also present in human amygdala tissue. [1]

This strengthens biological relevance, but it does not demonstrate the same causal chain in living people. Postmortem gene-expression differences are associations: they cannot establish whether altered ciliary signaling caused illness, resulted from illness, reflected treatment exposure or arose from another factor.

## The accuracy box: what the evidence does and does not show

- Supported: chronic stress in mouse models was associated with shorter primary cilia and altered molecular activity in amygdala astrocytes. [1]
- Supported: restoring cilia-related signaling through chemogenetics or S1PR1 targeting improved several molecular and behavioral measures in stressed mice. [1]
- Supported: ponesimod is an FDA-approved S1P-receptor modulator for relapsing forms of multiple sclerosis. [2]
- Not established: that chronic stress shortens astrocyte cilia in living human brains in the same way.
- Not established: that ponesimod treats anxiety, depression or chronic stress in people. No human psychiatric trial was part of this study. [1][2]
- Too strong: saying the medicine fully 'reversed anxiety and depression.' The paper measured partial improvement in selected stress-related mouse behaviors, not remission from human disorders. [1][4]
- Promising but early: human tissue showed related gene-expression differences, but those observations were correlational. [1]

## Why astrocytes and cilia matter

The study broadens the search for stress mechanisms beyond neuronal firing. Astrocytes regulate the chemical environment around synapses, interact with blood vessels and participate in circuit function. Their primary cilia provide a compact signaling hub through which extracellular messages can influence the cell. Government-indexed studies show that astrocytic cilia contribute to cellular specialization and can change under reactive conditions, supporting the idea that cilia are biologically active structures rather than decorative appendages. [3][6]

The UCLA result therefore identifies a testable chain: chronic stress alters astrocytes; their cilia shorten; manipulating cilia-linked receptor signaling changes molecular signatures and selected behaviors. Because multiple steps were experimentally manipulated, the mouse evidence goes beyond a simple correlation. [1] Translation to humans, however, remains a separate question.

## What needs to happen next

1. Independent laboratories need to reproduce the cilia and behavioral findings across mouse strains, sexes and different stress paradigms.
2. Researchers need to determine which S1PR1 effects arise in astrocytes and which may come from immune or other cells, because ponesimod acts systemically. [1][2]
3. Human studies must establish whether cilium-related changes can be measured safely and whether they track symptoms, treatment response or disease course.
4. Any psychiatric use of ponesimod would require controlled clinical testing for dose, effectiveness and safety; its existing FDA approval does not answer those questions. [2]
5. Mechanism-focused trials would need to show that the intended biological target is engaged, an approach NIMH highlights as central to modern therapeutic development. [7]

The most defensible conclusion is narrower than the headline claim but still important: UCLA researchers identified astrocyte primary cilia in the amygdala as a modifiable part of the stress response in mice, and an already-approved drug provides a concrete tool for testing that mechanism further. [1][2] Whether that path becomes a treatment for people is unknown.

## Sources and further reading

- [1] UCLA Health — 'Study identifies stress-response cells, points to new treatment target' (4 September 2026): https://www.uclahealth.org/news/release/study-identifies-stress-response-cells-points-new-treatment
- [2] U.S. Food and Drug Administration — Ponvory (ponesimod) prescribing information, initial U.S. approval 2021: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf
- [3] PubMed, U.S. National Library of Medicine — 'Primary cilia signaling in astrocytes mediates development and regional-specific functional specification' (2024): https://pubmed.ncbi.nlm.nih.gov/39103557/
- [4] National Institute of Mental Health — 'What Can Animals Tell Us About Mental Illnesses?': https://www.nimh.nih.gov/about/director/messages/2019/what-can-animals-tell-us-about-mental-illnesses
- [5] National Institute of Mental Health — 'A Hypothesis-Based Approach: The Use of Animals in Mental Health Research': https://www.nimh.nih.gov/about/director/messages/2019/a-hypothesis-based-approach-the-use-of-animals-in-mental-health-research
- [6] PubMed Central, U.S. National Library of Medicine — 'Diverged morphology changes of astrocytic and neuronal primary cilia under reactive insults': https://pmc.ncbi.nlm.nih.gov/articles/PMC7053156/
- [7] National Institute of Mental Health — '2020 NAMHC Workgroup on Drug Development': https://www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/reports/2020-namhc-workgroup-on-drug-development

---

_Canonical article: [https://brainwavepost.com/article/ucla-astrocyte-primary-cilia-chronic-stress-ponesimod-2026](https://brainwavepost.com/article/ucla-astrocyte-primary-cilia-chronic-stress-ponesimod-2026) — © BrainWavePost. Educational content; see the article page for full disclaimers._